(Q34602374)

3 August 2017

title

Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (English)

1 reference

3 August 2017

Baiju Malde

1

1 reference

3 August 2017

Jane Regalado

series ordinal

2

1 reference

3 August 2017

Paul A Greenberger

series ordinal

3

1 reference

3 August 2017

publication date

1 January 2007

1 reference

Annals of Allergy, Asthma & Immunology

3 August 2017

published in

1 reference

3 August 2017

volume

98

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

57-63

1 reference

Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

ACE inhibitor-induced angioedema. Incidence, prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Increased sensitivity to bradykinin among African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Changing trends in angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Clinical features and severity grading of anaphylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Treatment of hypertension in patients with renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960860-5

7 January 2021

10.1016/S1081-1206(10)60860-5

Identifiers

DOI

1 reference

3 August 2017

1 reference